














Lower tidal volume strategy (&3 ml/kg)
combined with extracorporeal CO2 removal
versus ‘conventional’ protective ventilation
(6 ml/kg) in severe ARDS
The prospective randomized Xtravent-study
Received: 12 July 2012
Accepted: 29 November 2012
Published online: 10 January 2013
 The Author(s) 2013. This article is published
with open access at Springerlink.com
T. Bein and S. Weber-Carstens contributed
equally to the work.
This article is discussed in the editorial
available at doi:10.1007/s00134-012-2805-8.
Electronic supplementary material
The online version of this article
(doi:10.1007/s00134-012-2787-6) contains
supplementary material, which is available
to authorized users.
T. Bein  B. M. Graf
Department of Anesthesia and Operative
Intensive Care, Regensburg University
Hospital, Regensburg, Germany
S. Weber-Carstens 
A. Goldmann  K.-D. Wernecke
Department of Anesthesia and Operative
Intensive Care Medicine, Charite´
Universita¨tsmedizin Berlin, Campus
Virchow-Klinikum and Campus Charite´
Mitte, Berlin, Germany
T. Mu¨ller  M. Lubnow




Intensive Care Unit, Department of Internal
Medicine I, Vienna General Hospital,
Medical University of Vienna,
Vienna, Austria
J. Brederlau




Department of Anaesthesia and Critical
Care, University of Wu¨rzburg, Wu¨rzburg,
Germany
R. Dembinski







Department of Internal Medicine III,
Vienna General Hospital,
Medical University of Vienna,
Vienna, Austria
A. Philipp




Interdepartmental Division of Critical Care
Medicine, Department of Medicine, Keenan
Research Center at the Li Ka Shing
Knowledge Institute of St. Michael’s
Hospital, University of Toronto,
Toronto, Canada
K.-D. Wernecke
SOSTANA GmbH, Biometric Statistical
Analyses, Berlin, Germany
T. Bein ())






respiratory distress syndrome is
characterized by damage to the lung
caused by various insults, including
ventilation itself, and tidal hyperin-
flation can lead to ventilator induced
lung injury (VILI). We investigated
the effects of a low tidal volume (VT)
strategy (VT & 3 ml/kg/predicted
body weight [PBW]) using pumpless
extracorporeal lung assist in estab-
lished ARDS. Methods: Seventy-
nine patients were enrolled after a
‘stabilization period’ (24 h with
optimized therapy and high PEEP).
They were randomly assigned to
receive a low VT ventilation (&3
ml/kg) combined with extracorporeal
CO2 elimination, or to a ARDSNet
strategy (&6 ml/kg) without the
extracorporeal device. The primary
outcome was the 28-days and 60-days
ventilator-free days (VFD).
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Secondary outcome parameters were
respiratory mechanics, gas exchange,
analgesic/sedation use, complications
and hospital mortality.
Results: Ventilation with very low
VT’s was easy to implement with
extracorporeal CO2-removal. VFD’s
within 60 days were not different
between the study group (33.2 ± 20)
and the control group (29.2 ± 21,
p = 0.469), but in more hypoxemic
patients (PaO2/FIO2 B150) a post hoc
analysis demonstrated significant
improved VFD-60 in study patients
(40.9 ± 12.8) compared to control
(28.2 ± 16.4, p = 0.033). The mor-
tality rate was low (16.5 %) and did
not differ between groups.
Conclusions: The use of very low
VT combined with extracorporeal
CO2 removal has the potential to
further reduce VILI compared with a
‘normal’ lung protective manage-
ment. Whether this strategy will
improve survival in ARDS patients
remains to be determined (Clinical
trials NCT 00538928).
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Introduction
Acute respiratory distress syndrome (ARDS) is charac-
terized by damage to the lung parenchyma, caused by
either indirect or direct insults, including ventilation itself
[1]. Tidal hyperinflation and cyclic alveolar recruitment/
derecruitment during mechanical ventilation can lead to
an entity called ventilator induced lung injury (VILI)
[2, 3]. A multi-centered clinical trial demonstrated that a
lung protective strategy with tidal volumes (VT’s) of 6 ml/kg
predicted body weight (PBW), and plateau pressures
B30 cmH2O decreased mortality by a relative 22 %
compared to control [4]. A post hoc analysis of this study
[5] found that the lower the plateau pressure (Pplat), the
better the patient’s chances of survival, even for Pplat
substantially \30 cmH2O, and these data suggested that
even lower tidal volumes might further improve survival.
Grasso and colleagues [6] demonstrated that many ARDS
patients ventilated using the ARDSNet strategy with
table-based PEEP have a stress index indicating alveolar
hyperinflation.
These data would suggest the use of even lower tidal
volumes, but in severe ARDS the implementation of such
a strategy may be limited by a therapeutic dilemma due to
the increased likelihood of more severe hypercapnia and
acidosis. The impact of hypercapnia on lung injury or on
systemic effects including remote organ damage (myo-
cardial insufficiency, renal failure, and hepatic/intestinal
ischemia) is somewhat controversial [7, 8], delaying or
preventing the implementation of adequate lung-protec-
tive strategies [9].
In the last few years, extracorporeal, pumpless arterio-
venous approaches to CO2 removal using an artificial
membrane lung have been developed and tested for
clinical use retrospectively in 90 patients [10] demon-
strating marked carbon dioxide removal and moderate
oxygenation improvement. Additionally, in a prospective
cohort study Terragni and coworkers [11] used a CO2
removal device to reduce tidal volume lower than 6 ml/kg
and observed an improvement of morphological markers
of lung protection. However, their study was not a
randomized clinical trial and there was no concurrent
control group. We set out to investigate the effects of
combining a very low VT (3 ml/kg PBW) with arterio-
venous extracorporeal CO2-elimination (avECCO2-R) in
patients suffering from established ARDS.
We hypothesized mechanical ventilation using lower
tidal volumes (3 ml/kg) assisted by avECCO2-R would
enhance lung protection and hence increase 28-day and
60-day ventilator-free days, compared with mechanical
ventilation using conventional tidal volumes (6 ml/kg).
Methods
Patients
The study was approved by the ethics committee of the
Regensburg University Hospital (reference 07/012), and
the ethics committees of all involved study centers.
Before enrolment, written informed consent was obtained
from the legal proxy of each patient. Patients were
enrolled from September 2007 through December 2010 at
eight intensive care units (ICU) in Germany and two
ICU’s in Austria.
Entry criteria were: (1) presence of ARDS according
to the American-European Consensus Conference [12]
defined by bilateral infiltrates on chest X-ray, and a PaO2/
FIO2 \200 present for at least 2 h. At the time of
screening patients could not have any evidence of left
ventricular failure; (2) age C18 years; (3) history of
mechanical ventilation \7 days); (4) plateau pressure
[25 cmH2O at defined ventilator settings (PEEP/FIO2-
table ? VT = 6 ml/kg); (5) absence of severe hemody-
namic instability with high demand for vasopressors
(mean arterial pressure C70 mmHg with continuous
norepinephrine infusion B0.4 lg/kg/min). Exclusion cri-
teria were: decompensated heart insufficiency, acute
coronary syndrome, severe chronic obstructive pulmonary
disease, advanced malignancy with life expectancy
\6 months, chronic dialysis treatment, lung transplant
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patients, proven heparin-induced thrombocytopenia
(HIT), morbid obesity (body mass index [40 kg/m2),
cirrhosis of the liver Child Class CB (Child–Pugh scores
C7), or acute fulminant hepatic failure, severe peripheral
arterial occlusive disease, absence of limb doppler pulse,
and acute brain injury (Glasgow Coma Scale B9).
To identify patients presenting with established ARDS
and to help further rule out patients with acute cardio-
genic pulmonary edema, the screening was followed by a
stabilization period for 24 h, characterized by lung pro-
tective mechanical ventilation with high PEEP
(C12 cmH2O), the use of supportive measures, and
hemodynamic evaluation (echocardiography). Patients
who had ARDS criteria (PaO2/FIO2 \200) after 24 h
despite optimal supportive treatment were identified as
those with established ARDS [13], and were randomized
through phone hot line by a random number table gen-
erated by the involved statistician with respect to the
stratum pulmonary/non-pulmonary ARDS (Fig. 1). The
principal investigator (TB) performed visits aimed at
information and supervision of the study protocol in the
participating centers. An independent Data Safety Moni-
toring Board monitored the study.
Treatment of the study group
The intensive care management in both groups followed
the ‘best clinical evidence’ recommended by the
European Society of Intensive Care Medicine [14]. The
daily monitoring included the assessment of awakeness/
sedation (Richmond Agitation Sedation Scale [RASS])
and the daily evaluation of the Sequential Organ Failure
Assessment (SOFA) and the Simplified Acute Physiology
Score (SAPS-II).
After randomization to the treatment group, percuta-
neous cannulation and initiation of pumpless extra-
corporeal lung assist (iLA AV, Novalung, Heilbronn,
Germany) was performed. Unlike ‘‘classic’’ pump-driven
extracorporeal carbon dioxide removal, iLA does not
require a blood pump, because the extremely low resis-
tance of this circuit allows flows of about 1–2 l/min with
normal arterial pressures (for more detailed description:
[10, 15]). Evaluation, cannulation and clinical monitoring
for avECCO2-R can be found in electronic supplementary
material (ESM).
After initiation of avECCO2-R, adaptation of the
ventilation strategy according to study protocol was per-
formed as follows: a rapid titration down to VT 3 ml/kg/
PBW, PEEP following ARDSNet ‘‘high-PEEP/FIO2’’
table [16], respiratory rate 10–25/min with an inspiratory/
expiratory ratio of 1:1. Termination of the avECCO2-R
therapy and decannulation was performed according to a
defined algorithm (see ESM).
Treatment of the control group
The ventilatory management followed the algorithm of
the study group except for the use of a VT = 6 ml/kg/
PBW. The target blood gases for both groups were: PaO2
C60 mmHg and arterial pH C7.2. The use of buffering
(tris-(hydroxymethyl) aminomethane [TRIS]) was per-
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Weaning and extubation procedures
In both groups daily screening was performed as a pre-
condition for carrying out a spontaneous breathing trial
(SBT): ability to breathe spontaneously (FIO2 B0.4, SaO2
C90 %, PEEP B8 cmH2O, hemodynamic stability, RASS
score C-1, body temperature \38.5).
SBT was carried out over 1 h with augmented sponta-
neous breathing (ASB) 5 cmH2O with an active humidifier
or, 10 cmH2O with HME filter (PEEP B8 cmH2O, flow
trigger \3 l/min). Patients were extubated when no dete-
rioration was observed over a 1 h period.
Data collection
At the time of screening (24 h prior to randomization)
physiologic data were recorded and relevant laboratory,
radiographic and clinical findings were collected. Through-
out the complete study period, data on ventilator settings,
laboratory, physiologic, radiographic and interventional data
were recorded. Relevant data of the ventilation management
(VT, PEEP, Pplat, minute ventilation, proportion of sponta-
neous ventilation on minute ventilation, arterial oxygen
saturation) as well as results of the blood gas analyses (PaO2,
PaCO2, pH) were recorded three times daily (8 a.m., 2 p.m.,
10 p.m.) and the mean values of repeated measures were
used for further analysis. SOFA score, SAPS-II and RASS
scores were calculated daily (8 a.m.).
In addition, in a subgroup of study patients of the
Regensburg University Hospital, depending on ‘in-the-
daytime’-availability of requested lab values, the levels of
proinflammatory cytokines (tumour necrosis factor
[TNF], interleukin 6 [IL-6] and interleukin 8 [IL-8]) were
assessed from serum probes of avECCO2-R-patients
(n = 20) and control patients (n = 15) at various time
points during the study, since the measurement of these
parameters is part of the routine laboratory program in
this hospital. Furthermore, in all participating centers the
daily cumulative doses of vasopressors (norepinephrine,
adrenaline, dobutamine), sedative and analgesic agents
(sufentanil, propofol, midazolam) and net fluid balances
were calculated in each patient and recorded.
Primary outcome
The primary outcome parameter was the proportion of
days without assisted ventilation in a 28-day period
(‘‘ventilator-free’’ days within 28 days [28-VFD]) and in
a 60 days period (‘‘ventilator-free’’ days within 60 days
[60-VFD]) [17].
Secondary outcomes
Secondary outcomes were: inspiratory plateau pressure
levels (Pplat), the proportion of spontaneous breathing as a
percentage of the minute ventilation (automatically cal-
culated by the ventilator’s software), the RASS score,
hemodynamic changes, the incidence of complications or
adverse reactions, the frequency and duration of other
adjunctive therapeutic measures, transfusion requirements
[packed red blood cell transfusions (units), fresh frozen
plasma units, platelet transfusion], the daily cumulative
doses of analgesic and sedative agents, cumulative cate-
cholamine requirements/24 h throughout the study period,
frequency and duration of renal replacement therapy, the
number of failing organs, the ‘‘organ-failure-free days’’
within 28 days after randomisation, and ‘‘in-hospital’’
mortality.
Statistical analysis
Assuming an increase in 28-VFD from 6.0 ± 10 (control
group) to 11.0 ± 8 (study group [13]), we estimated that
53 patients would be needed per group for a power of 0.8
and an alpha of 0.05 (calculation by Charite` Centrum fu¨r
Therapieforschung, Berlin, Germany). We assumed a
‘‘drop-out-rate’’ of 10 % and we calculated that 120
patients would need to be enrolled. However, after an
interim analysis with 56 patients by the Data Safety
Monitoring Board, it was decided to limit the study period
to 3 years, since a statistical significant difference was not
expected in a longer study period.
We used a Student’s t-test, the Wilcoxon test, the chi-
square test or Fisher’s exact test to assess differences
between the groups, as appropriate. A Kaplan–Meier
curve was calculated and plotted to assess the days until
successful weaning from the ventilator. Furthermore, a
nonparametric analysis of longitudinal data in factorial
experiments was performed. Changes in interesting clin-
ical outcomes with respect to time were analyzed using
multivariate nonparametric analysis of longitudinal data
in a two-factorial design (1st [independent] factor:
groups, 2nd [dependent] factor: repetitions in time).
Therefore, all the time points were simultaneously com-
pared on the corresponding response curves (analysis
according to Brunner [Brunner-analysis 18]). Addition-
ally, a post hoc analysis was performed in patients with
greater hypoxemia (PaO2/FIO2 B150) regarding primary
outcome parameters. The reported P values are two-sided
and significance was set at P \ 0.05.
Results
Between September 2007 and December 2010, 40
patients were randomized to avECCO2-R and 39 patients
to control. Baseline data are given in Table 1. Patients did
not differ with respect to age and body mass index, but in
the avECCO2-R-group there were more patients with
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secondary ARDS. Ventilatory and gas exchange data are
shown in Table 2.
Initially all patients were ventilated with high PEEP
and low tidal volume according to the ARDSNet protocol,
and had moderate hypercapnia. At randomization there
were no significant differences regarding mean arterial
pressure, heart rate or demand vasopressor uses (data not
shown). However, there was a significantly lower PaO2/
FIO2-ratio in the intervention arm. The mean duration of
iLA-treatment was 7.4 ± 4 days with a mean blood flow
of 1.3 ± 0.2 l/min throughout the treatment period.
Primary outcome results
We found no statistical differences in VFD-28 or VFD-60
between groups, (Table 3), but a post hoc analysis dem-
onstrated that surviving patients with greater hypoxemia
(PaO2/FIO2 B150 at randomization) treated with
avECCO2-R had a significantly shorter period of ventila-
tion (VFD-60 = 40.9 ± 12.8) compared to control (28.2 ±
16.4, p = 0.033) Fig. 2). Non-pulmonary organ failure free
days within 60 days, intensive care and hospital days were
not statistically different between groups.
Secondary outcome results
After insertion of pumpless extracorporeal lung assist,
a VT of 3 ml/kg PBW was achieved in most patients
which increased moderately (as spontaneous breathing
increased) to day 6 after randomization (Fig. 3), while in
control patients VT increased from 6 ml to 8 ml/kg/PBW
(p \ 0.001 between groups). Minute ventilation was sig-
nificantly decreased, and the difference between plateau
pressure and PEEP (Pplat - PEEP) was significantly
reduced in study patients compared to control.
The fractional amount of augmented spontaneous
breathing as a percent of total minute ventilation was
significantly increased from day 3 in avECCO2-R com-
pared to control (Fig. 4).
In line with previous data, extracorporeal CO2
removal required higher FIO2 which is thought to be due
to the lower partial pressure of alveolar oxygen (PAO2)
secondary to a decreased lung respiratory quotient [19],
and due to a reduction in functional residual capacity with
a VT of 3 ml/kg compared to 6 ml/kg [20]. PaCO2-values,
arterial pH, and mean respiratory rates/min were similar
between groups, but mean PEEP levels tended to be
elevated in the study group. During the study period,
patients with avECCO2-R had a modest reduction in MAP
without increased demand for continuous norepinephrine
infusion.
The cumulative amount of opioid (sufentanil) and
benzodiazepine infusion (midazolam) was significantly
lower in the study group, but mean RASS-scores were not
different between groups during the study period (Fig. 5,
ESM).
The number of units of red blood cells transfused was
significantly higher in the avECCO2-R -group in the per-
iod between randomization and day 10 (3.7 ± 2.4 units
RBC) compared with control (1.5 ± 1.3, p \ 0.05). The





Age (years) 49.8 ± 12 48.7 ± 17
Gender (male/female) 38/2 30/9
Lung Injury Score (Murray) 2.8 ± 0.7 2.7 ± 0.8







Massive transfusion 1 0
Trauma 3 1
Pulmonary





Lung contusion 6 9
Inhalation 1 0
Comorbidities
Diabetes mellitus 2 3
COPD 5 3
Arterial hypertension 10 7
Coronary artery disease 1 1
Chronic renal impairment 2 0
Other 19 15
Atrial fibrillation 3 2
Alcohol use disorder 2 3
Obesity 2 3
The data are presented as mean ± standard deviation or absolute
numbers
Table 2 Ventilation parameters and gas exchange after 24-h






PaO2/FIO2 152 ± 37 168 ± 37 0.044
PaCO2 (mmHg) 57.3 ± 12 54.3 ± 9 0.352
Arterial pH 7.34 ± 0.07 7.36 ± 0.07 0.317
VT (ml/kg, PBW) 5.9 ± 1.2 6.0 ± 0.6 0.495
Minute ventilation
(l/min)
9.9 ± 1.6 9.8 ± 2.4 0.745
Frequency/min 22.4 ± 3 22.7 ± 3.5 0.854
PEEP (cmH2O) 16.1 ± 3 16.0 ± 3 0.898
Plateau pressure
(cmH2O)
29.0 ± 5 28.0 ± 7 0.384
Delta (PEEP-Plateau)
(cmH2O)
12.9 ± 4 12.4 ± 4 0.475
FIO2 0.62 ± 0.2 0.53 ± 0.1 0.028
The data are presented as mean ± standard deviation
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incidence of avECCO2-R -related adverse events was low
(3 patients = 7.5 %): in one patient, transient ischemia of
the lower limb was observed, while two patients devel-
oped a ‘false’ aneurysm as a result of arterial cannulation.
The overall hospital mortality was low (16.5 %) and we
found no significant difference between avECCO2-R-
group (17.5 %) and control (15.4 %).
Results of the cytokine assessments
TNF-a, IL-6, and IL-8 levels are presented in Table 4.
Serum TNF-a levels remained unchanged during the early
study period in both groups, while IL-6 levels decreased
significantly in the avECCO2-R-group, but not in the
control group within 24 h after study initiation. IL-8
levels increased in the first few study days in the control
group, but not in study patients.
Discussion
Lung protective ventilation using VT’s of 6 ml/kg/PBW
and limiting Pplat to 30 cmH2O improves outcomes in
patients with acute lung injury [4]. However, the concept
that this approach may not be sufficiently lung protective
in all patients has been suggested by a post hoc analysis of
the ARDSNet data [5], by animal investigations [21],
human physiological studies [3], and by a clinical study
[11]. We extended these findings in patients with severe
established ARDS by performing a prospective
Table 3 Outcome parameters of the study
All patients Subgroup: PaO2/FIO2 \150
avECCO2-R Control p avECCO2-R Control p
Ventilator-free-days-28 10.0 ± 8 9.3 ± 9 0.779 11.3 ± 7.5 5.0 ± 6.3 0.033
Ventilator-free-days-60 33.2 ± 20 29.2 ± 21 0.469 40.9 ± 12.8 28.2 ± 16.4 0.033
Non-pulmonary organ failure free days-60 21.0 ± 14 23.9 ± 15 0.447 24.1 ± 7.5 29.0 ± 17.7 0.428
Lung injury score on day 10 2.2 ± 0.6 2.1 ± 0.5 0.854 2.3 ± 0.8 2.2 ± 0.5 0.601
Length of stay in hospital (days) 46.7 ± 33 35.1 ± 17 0.113 42.0 ± 16.6 40.3 ± 15.7 0.815
Length of stay in ICU (days) 31.3 ± 23 22.9 ± 11 0.144 25.9 ± 13.1 31.0 ± 12.7 0.258
In-hospital mortality 7/40 (17.5 %) 6/39 (15.4 %) 1.000 1/21 (4.8 %) 1/10 (10 %) 0.563
Fig. 2 Post-hoc analysis: probability of successful weaning in patients presenting with PaO2/FIO2 B150 versus [150 (only surviving
patients)
852
randomized trial using a strategy of very low tidal volume
ventilation (3 ml/kg) and an extracorporeal lung assist
system providing CO2-elimination.
The main findings of our study are: (1) Ventilation with
&3 ml/kg PBW combined with avECCO2-R was safe and
feasible, and did not result in physiologically relevant
hypercapnia/acidosis. (2) The use of extracorporeal CO2-
elimination was associated with a significant reduction in
analgesic and sedative use, and resulted in an increased
ratio of spontaneous breathing compared to control. (3)
The serum levels of the pro-inflammatory cytokine IL-6
were significantly reduced in the early study period in
patients treated with very low VT compared to control
patients, and (4) Mechanical ventilation using lower tidal
volumes (3 ml/kg) assisted by extracorporeal CO2-removal
was not associated with a significant reduction of the
period of mechanical ventilation within 28 or 60 days or
the intensive care and hospital stay, but a post hoc analysis
demonstrated that ARDS patients who were more hypox-
emic (PaO2/FIO2 B150 at randomization) at baseline and
who were treated with the low VT strategy had a signifi-
cantly shorter ventilation period.
The strength of this study is the evaluation of patients
with ‘established’ ARDS: We only accepted patients for
Fig. 3 Mean tidal volumes (ml per kg predicted body weight), minute ventilation and difference of plateau pressure and PEEP
(Pplat - PEEP), in the treatment and control groups during the study period
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randomization who passed a ‘stabilization period’ (24-h
ventilation period with high PEEP) and other measures of
optimization and who continued to have persistent
impairment of oxygenation (PaO2/FIO2 B200). In a recent
analysis [13] this patient group was identified as having a
high mortality compared to patients with PaO2/FIO2
[200. However, our study has limitations. Due to a
restriction of the enrolment period to 3 years and a ‘strict’
recruitment protocol we did not reach the pre-specified
sample size. Another limitation is the fact that we only
enrolled patients with stable hemodynamics, since severe
cardiovascular instability was an exclusion criterion for
the pumpless circuit. This exclusion criterion might
explain the very low mortality rate in the overall study
population.
Tidal hyperinflation [3, 4, 22], and cyclic recruitment/
derecruitment [23, 24] are important mechanisms leading
to ventilator-induced lung injury in patients with ARDS,
but sufficient clinical data are lacking indicating that a
reduction of these phenomena is beneficial. The inho-
mogeneously injured lung leads to heterogeneous
distribution of airway pressure and VT, resulting in partial
hyperinflation, cyclic opening and closing of moderate
injured lung regions, and no ventilation in atelectatic
regions, making it difficult to chose a single VT that
completely limits ‘global’ stress/strain injury [25]. Since
it is not possible to adopt ventilation to the protective
‘demands’ of different lung regions, we hypothesized that
even a small VT of 6 ml/kg might aggravate VILI, and
therefore we carried out the first reported randomized
Fig. 4 Percent of spontaneous ventilation on minute ventilation and oxygenation (PaO2/FIO2) in the treatment and control groups during
the study period
Table 4 The serum level of tumor necrosis factor (TNF), interleukin 6 (IL-6), and interleukin 8 (IL-8) in treatment and control patients
(median values and 25/75 percentiles)
TNF (pg/ml) Before begin of the study 24 h 48 h 72 h
avECCO2-R (n = 20) 19.8 (13.8–23) 20 (13.2–23.6) 15.3 (13.7–21.4) 22.5 (12.8–33.2)
Control (n = 15) 20.5 (14.2–26.8) 21 (13.9–48.6) 15.9 (13.6–28) 15.2 (12.7–25)
IL-6 (pg/ml)
avECCO2-R (n = 20) 163 (86–419) 85 (50–193)
$ 53 (20–109)$$ 60 (35–155)$
Control (n = 15) 97 (84–214) 111 (52–171) 102 (58–166) 64 (18–90)
IL-8 (ng/l)
avECCO2-R (n = 20) 72 (23–98) 65 (30–100) 71 (28–94) 81 (43–120)
Control (n = 15) 34 (23–49) 36 (24–126) 45 (29–529) 25 (17–191)
$ p \ 0.05 in comparison with before
$$ p \ 0.01 in comparison with before
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controlled study using a very low tidal volume lung
strategy.
Our data demonstrate the integration of augmented
spontaneous breathing in the ventilation management of
severe ARDS patients [26, 27] without a consequent
increase in tidal volume or in the demand for sedative
agents. We hypothesize that avECCO2-R might allow an
easy ‘switch’ from controlled low VT-ventilation to aug-
mented spontaneous breathing with minimal patient-
ventilator asynchrony. Although we did not formally
assess ineffective breathing or other signs of asynchrony,
we demonstrated that the respiratory rate was not different
between the groups, whereas the demand for sedation was
significantly lower in the avECCO2-R group. A reduction
of the hypercapnia likely resulted in decreased respiratory
drive as shown by Karagiannidis and coworkers [28]
using neurally adjusted ventilatory assist (NAVA).
In the present study, avECCO2-R required higher
fractional inspiratory oxygen concentration to maintain
adequate oxygenation, while both patient groups were
treated with the same high PEEP management. There are
two possible mechanisms to explain this finding. The first
is a decrease in alveolar ventilation due to the removal of
CO2 by the extracorporeal circuit [19], and the second
mechanism relates to potential de-recruitment of the lung
as demonstrated by Dembinski et al. [29] in a lung lavage
animal model (VT 3 ml/kg and avECCO2-R). However, in
this study the authors used a relatively low PEEP level
(5 cmH2O), where we used a ‘high PEEP strategy’. Such
a finding is of clinical relevance when considering
extracorporeal CO2-elimination as an adjunct measure for
lung protective ventilation [30] with very low VT [31]. A
‘safe border’ of VT to derecruitment is not known.
On the other hand use of very small VT’s might reduce
VILI. Using an experimental model, Frank et al. [21]
demonstrated that a reduction in VT from 6 to 3 ml/kg led
to a further reduction of epithelial and endothelial injury
(extravascular lung water, alveolar epithelial type I cell
antigen [RT 140]) in acid-injured rat lungs. In line with
these experimental findings we found that ventilation with
very low VT reduced serum levels of the proinflammatory
cytokine IL-6 compared with ‘normal’ protective VT.
In recent years, techniques of extracorporeal lung
support have become easier to use, with smaller devices
and greater efficacy. There is evidence that this has led to
a reduction in the rate of severe complications [32]. In the
present study only moderate complications attributable to
avECCO2-R occurred in three patients (7.5 %), and none
led to permanent impairment. This complication rate is
down from 24 and 12 % [10, 15], likely related to the use
of a screening algorithm, careful evaluation, new material
and a modified insertion technique [15].
In summary, we demonstrate that the use of very low
tidal volume (&3 ml/kg PBW) combined with extracor-
poreal elimination of carbon dioxide is feasible without
major side effects and might be beneficial in the treatment
of patients with severe ARDS. The integration of aug-
mented spontaneous breathing might be easier and more
comfortable with extracorporeal CO2-removal, and a
reduced demand for sedative and analgesic medication
could be advantageous. Future studies are required to
determine whether ‘ultraprotective’ ventilation will
improve survival in patients suffering from severe ARDS.
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